Hemoglobina glicosilada en población diabética en periodo de pandemia covid-19 en un centro de atención primaria

• Riveros, Daniel ^[1] ; Ortiz-Cabezas, Alex ^[1] ; Canela-Soler, Jaume ^[2] ; Monleón-Getino, Antonio ^[2] ; Ayala-Aldana, Nicolas ^[2]
  1. [1] Universidad Católica del Maule

     Universidad Católica del Maule

     Provincia de Talca, Chile

     
  2. [2] Universitat de Barcelona

     Universitat de Barcelona

     Barcelona, España

     
• Localización: Ciencia Latina: Revista Multidisciplinar, ISSN-e 2707-2215, ISSN 2707-2207, Vol. 7, Nº. 1, 2023, pág. 20
• Idioma: español
• DOI: 10.37811/cl_rcm.v7i1.4393
• Títulos paralelos:
  • Glycosylated haemoglobin in a diabetic population during covid-19 pandemic-period at primary care centre
• Enlaces
  • Texto completo (pdf)
  • Texto completo
• Resumen
  • español

    Introducción. La diabetes mellitus tipo 2 (DM2) es una enfermedad metabólica que afecta todas las aristas de la vida individual y familiar de la persona que la padece. La pandemia causada por el virus de SARS-COV-2 ha generado un problema relevante a nivel del sistema de salud, provocando una sobrecarga importante y una complejizarían de los servicios para atender la infección. Lo anterior, ha llevado a que muchas personas pierdan sus controles crónicos y no puedan cuidarse de manera adecuada. Métodos. La prueba de Wilcoxon se utilizó para comparar grupos de pacientes y variables continuas. Se aplicó un modelo de regresión lineal para estudiar la asociación entre la glicemia y la hemoglobina glicosilada. Se consideró un valor p <0.05 para aceptar la hipótesis alternativa de las pruebas estadísticas. Resultados. Se encontraron diferencias significativas entre población con niveles inferiores a 9% de hemoglobina glicosilada y niveles superiores o iguales a 9% en variables como glicemia, colesterol total, colesterol HDL, colesterol LDL y triglicéridos. En el modelo de regresión lineal se reportó R2  (0.61) y  (0.22) entre la glicemia y la hemoglobina glicosilada con significancia estadística en todos los niveles (valor p<0.05). Conclusiones.  Un mal ajuste de los niveles de HBA1C en población con DM2 podría generar una serie de comorbilidades como dislipidemias, hipertensión, enfermedad cardiovascular o infarto agudo al miocardio producto de la glucotoxicidad y lipotoxicidad.

  • English

    Introduction. Type 2 diabetes mellitus (DM2) is a metabolic disease that affects all aspects of the individual and family life of the person who suffers from it. The pandemic caused by the SARS-COV-2 virus has trigged a relevant problem at the level of the health system, causing a significant overload and a new multi-complexity in the patient treatment. The foregoing problem has led many people to lose the doctor visits and worsen their self-care in health. Methods. The Wilcoxon test was performed to compare groups of patients and the continuous variables. A simpler linear regression model was applied to study the association between glycemia and glycosylated haemoglobin. A p-value <0.05 was considered to accept the alternative hypothesis for the statistical tests. Results. Significant differences were founded between the population with glycosylated haemoglobin levels less than 9% and a level greater than or equal to 9% in variables such as glycemia, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. In the linear regression model, R2 (0.61) and   (0.22) were obtained between glycemia and glycosylated haemoglobin with statistical significance at all levels (p-value <0.05). Conclusions. A poor adjustment of HBA1C levels. in the population with DM2, could generate a series of comorbidities such as dyslipidaemia, hypertension, cardiovascular disease, or acute myocardial infarction because of glucotoxicity and lipotoxicity.

• Referencias bibliográficas
  • Ahmad Khan, H. (2007). Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta...
  • Andersen, G. E., Christiansen, J. S., Mortensen, H. B., Christiansen, K. M., Pedersen-Bjergaard, L., Kastrup, K. W., & Vestermark, S....
  • Begum, A., Irfan, S. R., Hoque, M. R., Habib, S. H., Parvin, S., Malek, R., Akhter, S., Sattar, S., & Sarkar, S. (2019). Relationship...
  • Benoit, S. R., Hora, I., Albright, A. L., & Gregg, E. W. (2019). New directions in incidence and prevalence of diagnosed diabetes in the...
  • Botana López, M. A., López Ratón, M., Tomé, M. A., Fernández Mariño, A., Mato Mato, J. A., Rego Iraeta, A., Pérez Fernández, R., & Cadarso...
  • Brockmeyer, M., Wies, E., Joerges, J., Sommer, J., Borgmann, S. O., Chernyak, N., Lin, Y., Parco, C., Schulze, V., Heinen, Y., Kelm, M., Icks,...
  • Buková, L., Galajda, P., Javorský, M., & Mokáň, M. (2020). Glycated haemoglobin as a marker of elevated LDL and TAG: a cohort study. Vnitrni...
  • Call, J. T., Cortés, P., & Harris, D. M. (2022). A practical review of diabetes mellitus type 2 treatment in primary care. Romanian Journal...
  • Cheng, Y. J., Imperatore, G., Geiss, L. S., Wang, J., Saydah, S. H., Cowie, C. C., & Gregg, E. W. (2013). Secular changes in the age-specific...
  • Crespo, R., Alvarez, C., Hernandez, I., & García, C. (2020). A spatially explicit analysis of chronic diseases in small areas: a case...
  • Erciyas, F., Taneli, F., Arslan, B., & Uslu, Y. (2004). Glycemic control, oxidative stress, and lipid profile in children with type 1...
  • Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment...
  • Feng, L., Nian, S., Zhao, Y., Bai, X., Luo, F., Luo, X., Xu, W., Ye, D., & Tong, Z. (2018). Higher HbA1c and/or glucose levels alter the...
  • Feng, X., Yang, Y., Zhuang, S., Fang, Y., Dai, Y., Fu, Y., Hu, Q., Yuan, Q., Tang, H., & Tang, L. (2021). Influence of Serum Albumin on...
  • Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology...
  • HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. (2015). Diabetes Care,...
  • Ketema, E. B., & Kibret, K. T. (2015). Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control;...
  • Khan, H. A., Sobki, S. H., & Khan, S. A. (2007). Association between glycaemic control and serum lipids profile in type 2 diabetic patients:...
  • Khaw, K. T., Wareham, N., Luben, R., Bingham, S., Oakes, S., Welch, A., & Day, N. (2001). Glycated haemoglobin, diabetes, and mortality...
  • Kishore, P., Kim, S. H., & Crandall, J. P. (2012). Glycemic control and cardiovascular disease: what’s a doctor to do? Current Diabetes...
  • Lind, M., Odén, A., Fahlén, M., & Eliasson, B. (2009). The true value of HbA1c as a predictor of diabetic complications: simulations of...
  • Martín-Timón, I., Sevillano-Collantes, C., Segura-Galindo, A., & Del Cañizo-Gómez, F. J. (2014). Type 2 diabetes and cardiovascular disease:...
  • Nayak, A. U., Holland, M. R., Macdonald, D. R., Nevill, A., & Singh, B. M. (2011). Evidence for Consistency of the Glycation Gap in Diabetes....
  • Nowakowska, M., Zghebi, S. S., Ashcroft, D. M., Buchan, I., Chew-Graham, C., Holt, T., Mallen, C., Van Marwijk, H., Peek, N., Perera-Salazar,...
  • Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K.,...
  • Seidu, S., Hambling, C., Holmes, P., Fernando, K., Campbell, N. S., Davies, S., & Khunti, K. (2022). The impact of the COVID pandemic...